trending Market Intelligence /marketintelligence/en/news-insights/trending/FKxnnI05b5fGHC777y_C3A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

vTv Therapeutics licenses diabetes, muscle weakness programs

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

vTv Therapeutics licenses diabetes, muscle weakness programs

VTv Therapeutics Inc. unit vTv Therapeutics LLC entered licensing agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. and Reneo Pharmaceuticals Inc.

Huadong secured exclusive and sublicensable rights to develop and commercialize vTv's glucagon-like peptide-1 receptor agonist program for the treatment of type 2 diabetes, including the compound TTP273, in China and certain other pacific rim countries, including Australia and South Korea.

The Chinese pharmaceutical company will pay an initial license fee of $8.0 million, up to $25.0 million in potential development and regulatory milestone payments, an additional $20.0 million in milestone payment if Hangzhou receives regulatory approval for a central nervous system indication and $50.0 million in potential sales-based milestones, as well as tiered royalty payments ranging from low-single to low-double digit rates.

VTv's subsidiary will also pay up to $3.0 million for a phase 2 clinical trial of TTP273 in patients with type 2 diabetes.

Meanwhile, Reneo secured exclusive sublicensable global rights to develop and commercialize vTv's program to prevent muscle weakness associated with PMV and critical injury.

As part of the deal, Reneo will pay the vTv unit an initial license fee of $3.0 million, potential development, regulatory and sales-based milestone payments up to $94.5 million and tiered royalty payments at mid-single- to low double-digit rates.

In addition, vTv received an ownership interest in Reneo's common stock.